PROCEPT BioRobotics PRCT
- Market cap
- $1.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $337.3M
- +23% on a year ago
- Net margin
- −32.5%
- Free cash flow yield
- −7.4%
PROCEPT BioRobotics trades at 3.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $337.3M over the last twelve months, up 23% on a year earlier with a −33% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $35.1M+73% | $43.6M+83% | $44.5M+83% | $53.4M+61% | $58.4M+66% | $68.2M+57% | $69.2M+55% | $79.2M+48% | $83.3M+43% | $76.4M+12% | $83.1M+20% | $94.5M+19% | |
| Cost of revenue | $16.2M+60% | $22.3M+70% | $19.5M+64% | $21.9M+49% | $21.5M+32% | $24.6M+10% | $25M+28% | $27.4M+25% | $29.3M+37% | $30.1M+22% | $29.2M+17% | $32.1M+17% |
| Gross profit | $18.9M+85% | $21.3M+99% | $25M+100% | $31.5M+71% | $36.9M+96% | $43.7M+106% | $44.2M+76% | $51.7M+64% | $54M+46% | $46.3M+6% | $53.9M+22% | $62.4M+21% |
| R&D | $11.6M+53% | $14.5M+50% | $13.1M+22% | $17.5M+51% | $16.6M+44% | $15.1M+4% | $16.4M+25% | $17.6M+1% | $18.2M+9% | $19.1M+27% | $21.5M+31% | $20.1M+14% |
| SG&A | $32.9M+33% | $36.3M+40% | $39.6M+31% | $40.8M+26% | $42.7M+30% | $48.3M+33% | $55.2M+39% | $56.3M+38% | $59M+38% | $58.3M+21% | $65.1M+18% | $69.7M+24% |
| −$25.6M+16% | −$29.6M+18% | −$27.6M−3% | −$26.8M+5% | −$22.4M−12% | −$19.7M−33% | −$27.4M−1% | −$22.2M−17% | −$23.2M+3% | −$31M+58% | −$32.6M+19% | −$27.4M+23% | |
| Interest expense | $1M−30% | $1.1M+30% | $1M+18% | $1M+7% | $1.1M+12% | $969K−14% | $877K−16% | $895K−13% | $919K−19% | $894K−8% | $818K−7% | $842K−6% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$24.8M | −$19.4M | n/a | n/a | −$31.7M+28% | −$26.8M+38% |
| n/a | n/a | n/a | n/a | n/a | n/a | −$47K | $136K | n/a | n/a | −$43K−9% | $94K−31% | |
| Net income | −$24.6M+9% | −$27.5M−2% | −$26M−9% | −$25.6M+1% | −$21M−15% | −$18.9M−31% | −$24.7M−5% | −$19.6M−24% | −$21.4M+2% | −$29.8M+58% | −$31.6M+28% | −$26.9M+37% |
| −$0.51+0% | −$0.54−14% | −$0.51−19% | −$0.50−11% | −$0.40−22% | −$0.35−35% | −$0.45−12% | −$0.35−30% | −$0.38−5% | −$0.53+51% | −$0.56+24% | −$0.47+34% | |
| 48.3M+8% | 50.6M+13% | 51M+13% | 51.6M+14% | 52M+8% | 53.8M+6% | 54.9M+8% | 55.4M+7% | 55.7M+7% | 56.1M+4% | 56.5M+3% | 57.1M+3% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest PROCEPT BioRobotics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PRCTPROCEPT BioRobotics | $1.1B | n/m | n/a | 3.4× | +23% | −32.5% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| Peer median | $1.3B | 31.2× | 38.6× | 2.2× | +8% | 7.7% |
Investors who own it
Investors we follow who held PROCEPT BioRobotics at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfoliotrimmed
More on PROCEPT BioRobotics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .